Literature DB >> 1055633

Action of bredinin on mammalian cells.

K Sakaguchi, M Tsujino, M Yoshizawa, K Mizuno, K Hayano.   

Abstract

Bredinin, a new nucleoside antibiotic, inhibited multiplication of several mammalian cell lines in culture and had a cytotoxic effect on L5178Y cells. Growth inhibition by bredinin was prevented by guanosine 5'-monophosphate (GMP), guanosine, or guanine but not by other purine or pyrimidine nucleotides, nucleosides, or bases. Inhibition by bredinin at a low GMP; but at higher concentrations of bredinin the inhibition was not reversed even when the concentration of GMP was raised. Addition of GMP after cellular damage had occurred produced no effect on the damaged cells but it prvented further damage. Bredinin caused marked chromosomal aberrations such as breakages, translocations, and fragmentation in L5178Y cells.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1055633

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Anti-arthritic activity of bredinin, an immunosuppressive agent.

Authors:  H Iwata; H Iwaki; T Masukawa; S Kasamatsu; H Okamoto
Journal:  Experientia       Date:  1977-04-15

2.  Small elevations of glucose concentration redirect and amplify the synthesis of guanosine 5'-triphosphate in rat islets.

Authors:  S A Metz; M Meredith; M E Rabaglia; A Kowluru
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 3.  The design and development of an immunosuppressive drug, mycophenolate mofetil.

Authors:  A C Allison; E M Eugui
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Antimalarial properties of bredinin. Prediction based on identification of differences in human host-parasite purine metabolism.

Authors:  H K Webster; J M Whaun
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

5.  Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis.

Authors:  Ryo Rokutanda; Mitsumasa Kishimoto; Sachiko Ohde; Hisanori Shimizu; Atsushi Nomura; Yasuhiro Suyama; Yuri Ohara; Kenichi Yamaguchi; Masato Okada
Journal:  Rheumatol Int       Date:  2013-01-03       Impact factor: 2.631

6.  mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.

Authors:  Alexander J Valvezan; Marc Turner; Amine Belaid; Hilaire C Lam; Spencer K Miller; Molly C McNamara; Christian Baglini; Benjamin E Housden; Norbert Perrimon; David J Kwiatkowski; John M Asara; Elizabeth P Henske; Brendan D Manning
Journal:  Cancer Cell       Date:  2017-10-19       Impact factor: 31.743

7.  Pharmacokinetics of bredinin in renal transplant patients.

Authors:  K Takada; S Asada; Y Ichikawa; T Sonoda; S Takahara; S Nagano; T Fukunishi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Rat lymphoid cell lines with HTLV-I production. III. Transmission of HTLV-I into rats and analysis of cell surface antigens associated with HTLV-I.

Authors:  T Yoshiki; N Kondo; T Chubachi; M Tateno; T Togashi; T Itoh
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 9.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

Authors:  Rand Naffouje; Punita Grover; Hongyang Yu; Arun Sendilnathan; Kara Wolfe; Nazanin Majd; Eric P Smith; Koh Takeuchi; Toshiya Senda; Satoshi Kofuji; Atsuo T Sasaki
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.